A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 28 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 24 Aug 2018.
- 28 Sep 2017 Status changed from completed to active, no longer recruiting.
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History